Unmanaged impurities can derail drug development.
Impurities can be introduced during formulation, manufacturing, packaging, or storage. They can compromise product quality, patient safety, and regulatory approval or compliance. If left undetected or uncontrolled, they may trigger costly recalls, delays, and reputational damage. To mitigate these risks, manufacturers should proactively control impurity levels at or below acceptable limits across the product lifecycle by using robust, validated analytical methods and optimizing production to meet patient needs.
USP empowers manufacturers with trusted impurity solutions.
To help companies stay ahead, USP provides Impurity Reference Standards for a wide range of drug products. These standards, along with Analytical Reference Materials like USP Pharmaceutical Analytical Impurities and validated methods in USP-NF official Monographs and general chapters, help support robust impurity profiling, ready-to-use analytical methods , and confident product release. USP’s scientific rigor and global recognition provide the foundation for reliable impurity management across the product lifecycle.